DNLI

Denali Therapeutics Inc. DNLI

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$3.60M

Quarter to Jun 30

Net income

$-127.55M

Quarter to Jun 30

Free cash flow

$-97.81M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$4.00B total
T. Rowe Price Investment Management, Inc.
$416.12M+89.9%
BlackRock, Inc.
$360.76M+7.6%
BAILLIE GIFFORD & CO
$307.62M-0.9%
STATE STREET CORP
$181.31M+12.4%
Temasek Holdings (Private) Ltd
$180.37M0.0%
VANGUARD PORTFOLIO MANAGEMENT LLC
$166.59M+5.8%
VANGUARD CAPITAL MANAGEMENT LLC
$161.41M+2.1%
FMR LLC
$116.66M-0.9%
GOLDMAN SACHS GROUP INC
$106.89M-5.7%
GEODE CAPITAL MANAGEMENT, LLC
$102.21M+6.6%
Holocene Advisors, LP
$100.44M+22.2%
BAKER BROS. ADVISORS LP
$96.05M+0.1%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$81.33M-28.7%
PRICE T ROWE ASSOCIATES INC /MD/
$80.66M+27.3%
UBS Group AG
$80.26M+21.4%
DIMENSIONAL FUND ADVISORS LP
$73.58M+6.3%
NORGES BANK
$72.65M--
Pictet Asset Management Holding SA
$71.89M+9.1%
Capital Research Global Investors
$65.99M+2.0%
Fisher Asset Management, LLC
$62.09M-0.9%
ALLIANCEBERNSTEIN L.P.
$57.31M+3.2%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$56.80M+1828.2%
Casdin Capital, LLC
$52.60M+11.1%
Crestline Management, LP
$49.14M-13.6%
PRINCIPAL FINANCIAL GROUP INC
$36.52M-4.0%
See all 294 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DNLI

Earnings Per Share

13fpro.ai/company/DNLI

Loading ratio trend…

DNLI key financials by period

Reported revenue, net income and operating margin by fiscal year, from Denali Therapeutics Inc.'s annual filings on SEC EDGAR.

Denali Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$330.5M$-145.2M-59.5%
FY 2022$108.5M$-326.0M—
FY 2021$48.7M$-290.6M—
FY 2020$335.7M$71.1M18.7%
FY 2019$26.7M$-197.6M—
FY 2018$129.2M$-36.2M-35.9%
Source: DNLI filings on SEC EDGAR →

DNLI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Denali Therapeutics Inc. (DNLI): stock profile, AI score and financials

Denali Therapeutics Inc. (DNLI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DNLI is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Denali Therapeutics Inc. reports quarterly revenue of $3.6M, net income of $-127.6M, free cash flow of $-97.8M. Top institutional holders of DNLI by reported 13-F value include T. Rowe Price Investment Management, BlackRock, BAILLIE GIFFORD, based on the most recent SEC filings. DNLI trades on the Nasdaq exchange and files with the SEC under CIK 1714899. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNLI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Denali Therapeutics Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1714899 →